Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lithium in PSP or CBD
NCT00703677Phase 2Completed
- Sponsor
- Westat
- Start
- Sep 2008
- Primary completion
- Jan 2010
- Modality
- DNA Intercalators/Alkylators
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of lithium in progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD), sponsored by Westat. Primary endpoint: Ability to Tolerate Lithium Carbonate at 28 weeks. Started Sep 2008; status: completed.
02
Drugs
lithium
03
Conditions
progressive supranuclear palsy (PSP)corticobasal degeneration (CBD)
Beyond the preview
Go deeper on NCT00703677.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00703677.